Generics  

Lupin Pharmaceuticals, Inc. entered the U.S. generic pharmaceutical market in 2003 with the ANDA approval for cefuroxime axetil. Since then we have received more than a dozen FDA approvals. Six of Lupin's 14 ANDA approvals were the first granted by the US FDA, reinforcing our ability to submit high quality dossiers and gain on time approvals.

We are vertically integrated, from process development of the API to the submission of dossiers for finished dosages. This provides control over the supply chain and the ability to offer quality products at the right time and at competitive prices.

Our integrated manufacturing capability provides a portfolio of the highest quality generic products.

Expanding the product portfolio, Lupin Pharmaceuticals, Inc. is geared to file 15 or more ANDA’s per year in some of the following areas:

	Oral and injectable cephalosporins;
	Cardiovascular;
	Controlled release ANDA’s;
	Paragraph IV’s.

Our oral and injectable cephalosporin facilities, US FDA approved manufacturing sites and the new tablet and capsule facility in Goa, allow us to file and manufacture a wide range of finished products for the US market.